FH:CC News and Press, FILAMENT HEALTH CORP.

FILAMENT HEALTH ANNOUNCES CLOSING OF WARRANT EXERCISE, NOTE CONVERSION AND CONCURRENT PRIVATE PLACEMENT OF COMMON SHARES Canada NewsWire VANCOUVER, BC , June 12, 2024 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) (" Filament " ...

FILAMENT HEALTH ANNOUNCES AUTHORIZATION OF PHASE 2 CLINICAL TRIAL FOR PEX010 IN THE TREATMENT OF METHAMPHETAMINE USE DISORDER Canada NewsWire Company study investigating PEX010, Filament's botanical psilocybin drug candidate, has been authorized by both FDA and Health Canada...

FILAMENT HEALTH ANNOUNCES WARRANT EXERCISE AND NOTE CONVERSION BY NEGEV CAPITAL AND CONCURRENT PRIVATE PLACEMENT OF COMMON SHARES TO BENJAMIN LIGHTBURN, CHIEF EXECUTIVE OFFICER Canada NewsWire VANCOUVER, BC , June 3, 2024 /CNW/ - Filament Health Corp. (OTCQB:...

FILAMENT HEALTH ANNOUNCES FIRST QUARTER 2024 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS Canada NewsWire VANCOUVER, BC , May 14, 2024 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage na...

FILAMENT HEALTH TO DISCUSS ITS DRUG DEVELOPMENT PLATFORM IN FIRESIDE CHAT WITH WATER TOWER RESEARCH ON APRIL 4, 2024 AT 12PM ET Canada NewsWire VANCOUVER, BC , April 3, 2024 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or ...

FILAMENT HEALTH REPORTS Q4 AND YEAR END 2023 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS Canada NewsWire VANCOUVER, BC , April 2, 2024 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natur...

FILAMENT HEALTH ANNOUNCES APPOINTMENT OF MICHAEL MESSINGER TO ITS BOARD OF DIRECTORS Canada NewsWire VANCOUVER, BC , March 28, 2024 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical‐stage na...

FILAMENT HEALTH ANNOUNCES SHIPMENTS OF BOTANICAL PSILOCYBIN TO FOUR COUNTRIES FOR CLINICAL INVESTIGATION Canada NewsWire Research institutions in the United States , Canada , Israel , and Belgium , including Johns Hopkins University , will study PEX010, Fil...

--News Direct-- Filament Health CEO Ben Lightburn joined Steve Darling from Proactive to share the groundbreaking news that the U.S. Food and Drug Administration (FDA) has given its approval for the Investigational New Drug application for PEX010, Filament Health's botanical psilocybin dr...

FILAMENT HEALTH COMPLETES THE FIRST EXPORT OF BOTANICAL PSILOCYBIN TO ISRAEL Canada NewsWire Hadassah University Hospital will study PEX010, Filament's botanical psilocybin drug candidate, for the treatment of post-traumatic stress disorder and obsessive-compulsive disorder ...